Literature DB >> 35156157

Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers.

Leonardo Marques da Fonseca1, Vanessa Amil da Silva2, Kelli Monteiro da Costa2, Jhenifer Santos Dos Reis2, José Osvaldo Previato2, Lucia Mendonça Previato3, Leonardo Freire-de-Lima4.   

Abstract

The characteristics that grant the most malignancy to cancer cells are the ability to evade apoptotic mechanisms and the capacity to migrate beyond the boundaries of the original tissue. Studies by our own group and others show that changes in glycosylation are now considered hallmarks of cancer cells and are also able to impact tumor malignancy. This study aims to evaluate changes in the glycosylation profile of the A549 lung cancer cells brought about by the induction of a MDR phenotype as well as investigate the relationship between drug resistance, the cell glycophenotype and EMT. We induced resistance by employing a continuous treatment with cisplatin. Our results demonstrate overexpression of ABC transporters as well as anti-apoptotic members of the Bcl-2 family, leading to a MDR phenotype. The cells also undergo a classic EMT process, displaying the iconic cadherin switch and increased of both total and oncofetal fibronectin, coupled with increased cell motility. We also managed to show changes in the expression of both glycosyltransferases and the glycan epitopes they are responsible for building. We also suggest that perhaps not only changes in cell sialylation are common during resistance induction but are essential to it.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atypical glycosylation; Cisplatin; Epithelial-mesenchymal transition; Glycophenotype; Human lung adenocarcinoma; Multidrug resistance phenotype

Mesh:

Substances:

Year:  2022        PMID: 35156157     DOI: 10.1007/s10719-022-10042-2

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  70 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 3.  DNA replication stress as a hallmark of cancer.

Authors:  Morgane Macheret; Thanos D Halazonetis
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

4.  Immature truncated O-glycophenotype of cancer directly induces oncogenic features.

Authors:  Prakash Radhakrishnan; Sally Dabelsteen; Frey Brus Madsen; Chiara Francavilla; Katharina L Kopp; Catharina Steentoft; Sergey Y Vakhrushev; Jesper V Olsen; Lars Hansen; Eric P Bennett; Anders Woetmann; Guangliang Yin; Longyun Chen; Haiyan Song; Mads Bak; Ryan A Hlady; Staci L Peters; Rene Opavsky; Christenze Thode; Klaus Qvortrup; Katrine T-B G Schjoldager; Henrik Clausen; Michael A Hollingsworth; Hans H Wandall
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-12       Impact factor: 11.205

Review 5.  Effects of Dietary Nutrients on Epigenetic Changes in Cancer.

Authors:  Nicoleta Andreescu; Maria Puiu; Mihai Niculescu
Journal:  Methods Mol Biol       Date:  2018

Review 6.  Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.

Authors:  Rochelle Frankson; Zhi-Hong Yu; Yunpeng Bai; Qinglin Li; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

Review 7.  The Frequency of Ras Mutations in Cancer.

Authors:  Ian A Prior; Fiona E Hood; James L Hartley
Journal:  Cancer Res       Date:  2020-03-24       Impact factor: 12.701

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-b]pyridine anticancer compound.

Authors:  Angela Mastelić; Vedrana Čikeš Čulić; Nikolina Režić Mužinić; Milena Vuica-Ross; David Barker; Euphemia Y Leung; Jóhannes Reynisson; Anita Markotić
Journal:  Drug Des Devel Ther       Date:  2017-03-14       Impact factor: 4.162

Review 10.  Cancer epigenetics: Moving forward.

Authors:  Angela Nebbioso; Francesco Paolo Tambaro; Carmela Dell'Aversana; Lucia Altucci
Journal:  PLoS Genet       Date:  2018-06-07       Impact factor: 5.917

View more
  3 in total

1.  Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages.

Authors:  Marcos Andre Rodrigues da Costa Santos; Jhenifer Santos Dos Reis; Carlos Antonio do Nascimento Santos; Kelli Monteiro da Costa; Pedro Marçal Barcelos; Karen Queiroz de Oliveira Francisco; Pedro Antônio Guimarães Notaroberto Barbosa; Emanuelle Damasceno Souza da Silva; Celio Geraldo Freire-de-Lima; Alexandre Morrot; Debora Decote-Ricardo; Israel Diniz-Lima; Jose Osvaldo Previato; Lucia Mendonca-Previato; Leonardo Marques da Fonseca; Leonardo Freire-de-Lima
Journal:  Immunol Res       Date:  2022-10-05       Impact factor: 4.505

2.  Glycobiology of Cancer: Sugar Drives the Show.

Authors:  Jhenifer Santos Dos Reis; Marcos André Rodrigues da Costa Santos; Daniella Pereira Mendonça; Stefani Ingrid Martins do Nascimento; Pedro Marçal Barcelos; Rafaela Gomes Correia de Lima; Kelli Monteiro da Costa; Celio Geraldo Freire-de-Lima; Alexandre Morrot; Jose Osvaldo Previato; Lucia Mendonça Previato; Leonardo Marques da Fonseca; Leonardo Freire-de-Lima
Journal:  Medicines (Basel)       Date:  2022-05-24

Review 3.  ST6Gal1: Oncogenic signaling pathways and targets.

Authors:  Sajina Gc; Susan L Bellis; Anita B Hjelmeland
Journal:  Front Mol Biosci       Date:  2022-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.